Company Overview and News

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-04-12 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BMA / Banco Macro S.A. 6-K (Current Report of Foreign Issuer)

2018-04-09 sec.gov
SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
BMA / Banco Macro S.A. 6-K (Current Report of Foreign Issuer)

2018-04-04 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-27 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-22 sec.gov
SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-20 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-09 sec.gov
SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-08 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-03-08 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-02-20 sec.gov
      SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549       FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   February 19, 2018       Commission File Number: 001-32827       MACRO BANK INC. (Translation of registrant’s name into English)       Sarmiento 447 Buenos Aires C1 1041 Tel: 54 11 5222 6500   (Address of registrant’s principal executive offices)       Indicate by check mark whether the registrant files or wi
Upvote Downvote

 
BMA / Banco Macro S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-02-20 sec.gov
  SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549                            FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   February 19, 2018                            Commission File Number: 001-32827                              MACRO BANK INC. (Translation of registrant’s name into English)                            Sarmiento 447 Buenos Aires C1 1041 Tel: 54 11 5222 6500   (Address of registrant’s principal
Upvote Downvote

 
Deutsche Bank (DB) Incurs Net Loss in Q4, Revenues Down

2018-02-02 zacks
Deutsche Bank AG (DB - Free Report) reported net loss of €2.2 billion ($2.6 billion) in fourth-quarter 2017, compared with net loss of €1.9 billion ($2.3 billion) in the year-ago quarter. The results were affected by non-cash charge of €1.4 billion resulting from a valuation adjustment on its deferred tax assets due to the tax reform.
Upvote Downvote

 
Mitsubishi UFJ (MTU) to Post Q3 Earnings: What's in Store?

2018-01-31 zacks
Mitsubishi UFJ Financial Group (MTU - Free Report) is scheduled to report third-quarter fiscal 2018 (ended Dec 31, 2017) results on Feb 2.
Upvote Downvote

 
Toronto-Dominion to Record $400M Loss on U.S. Tax Changes

2018-01-09 zacks
The Toronto-Dominion Bank (TD - Free Report) anticipates reduction in its first-quarter fiscal 2018 profits because of the changes in the U.S. tax code. The amount by which it expects its bottom line to reduce is US$ 400 million. The Tax Cuts and Jobs Act was passed by the Congress on Dec 22, 2017. The act, among other things, dropped the U.S. corporate tax rate to 21% from 35%. Though this act is expected to drive earnings over the long term, it has led many companies to declare write downs because the reduced rate changes the value of deferred tax assets already held by firms on their balance sheets.
Upvote Downvote

 
Will Itau Unibanco Get Conditional Nod for XP Holding Deal?

2017-12-28 zacks
Brazil’s antitrust watchdog has been suggested to give conditional approval to Itau Unibanco S.A., a subsidiary of Itau Unibanco Holding S.A. (ITUB - Free Report) for its share purchase agreement with XP Investimentos, S.A. (XP Holding), a Brazil-based brokerage firm. This news was reported by Reuters. Per a statement issued on Wednesday, the watchdog has been suggested by the superintendent of Cade, a competition regulator in Brazil, to give consent to the deal.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 05961W105